An Update on Refractory Hypertension.

Matanes, Faris; Khan, M Bilal; Siddiqui, Mohammed; Dudenbostel, Tanja; Calhoun, David; Oparil, Suzanne

Matanes, Faris; Khan, M Bilal; Siddiqui, Mohammed; Dudenbostel, Tanja; Calhoun, David; Oparil, Suzanne.

Afiliação

Matanes F; Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL, 35294-2180, USA. fmatanes03@gmail.com.
Khan MB; Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL, 35294-2180, USA.
Siddiqui M; Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL, 35294-2180, USA.
Dudenbostel T; Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL, 35294-2180, USA.
Calhoun D; Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL, 35294-2180, USA.
Oparil S; Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL, 35294-2180, USA.

Curr Hypertens Rep ; 24(7): 225-234, 2022 07.

Article em En | MEDLINE | ID: mdl-35384577

Assuntos

Hipertensão; Antagonistas de Receptores de Angiotensina/uso terapêutico; Inibidores da Enzima Conversora de Angiotensina/farmacologia; Inibidores da Enzima Conversora de Angiotensina/uso terapêutico; Anti-Hipertensivos/farmacologia; Anti-Hipertensivos/uso terapêutico; Pressão Sanguínea/fisiologia; Humanos

Palavras-chave

Primary aldosteronism; Renal denervation; Sleep apnea; Spironolactone; Sympathetic activation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hipertensão Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google